GLP-1 Medication Access and Medicaid Coverage in 2024: What the Research Actually Shows

Roughly 40 million Americans are enrolled in Medicaid, and a significant portion of them have type 2 diabetes — one of the most common, costly, and preventable chronic diseases in the country. For many of these men, GLP-1 receptor agonists like semaglutide and tirzepatide represent a genuine clinical breakthrough: medications that reduce blood sugar, promote meaningful weight loss, and, critically, reduce the risk of heart attack and death. And yet, a 2025 cross-sectional study published in Annals of Internal Medicine found that approximately 2.72 million Medicaid enrollees with diabetes — roughly 40% — had restricted access to GLP-1 receptor agonists as of March 2024. That number is not a rounding error. It represents millions of men who could be benefiting from evidence-based medicine but aren’t, largely because of where they live and who pays their insurance premiums.

This is not a simple story of bureaucratic inefficiency. It is a story about how policy decisions, insurance structures, and longstanding racial and socioeconomic disparities interact to determine who actually gets access to some of the most effective metabolic medications ever developed. If you are navigating Medicaid coverage, trying to understand your options, or simply following the science on GLP-1 access, here is what the research shows — and what it means for you.

The Coverage Patchwork: Why Your ZIP Code Determines Your Access

The United States does not have a single Medicaid program. It has 50 state programs, each with its own formulary rules, prior authorization requirements, and managed care contracts. This creates a deeply uneven landscape for GLP-1 access, and the data bear this out in stark terms.

The Annals of Internal Medicine study examined all 50 state Medicaid fee-for-service (FFS) plans and 273 nonelderly adult managed care organization (MCO) plans in March 2024. Among FFS plans, 60% offered unrestricted access to at least one GLP-1 receptor agonist — meaning a drug was listed on the preferred drug list without requiring prior authorization or step therapy. That sounds reasonably encouraging until you look at managed care, which is where most Medicaid enrollees actually receive their benefits. Among MCO plans, only 48% offered unrestricted GLP-1 RA availability, and the state-level variation was extreme: GLP-1 RA availability for MCO enrollees ranged from 0% to 99% depending on the state. Tirzepatide, the newer dual GLP-1/GIP agonist, was almost entirely restricted across all plan types.

The researchers used DPP-4 inhibitors — a less effective class of diabetes medication with no proven cardiovascular benefit — as a benchmark. The result was telling: 84% of FFS plans offered unrestricted access to DPP-4 inhibitors, compared to just 60% for GLP-1 receptor agonists. In MCO plans, 75% covered DPP-4 inhibitors unrestricted versus 48% for GLP-1 RAs. In other words, the Medicaid system is, in many cases, making it easier for patients to access a less effective, less protective drug class than one with documented cardiovascular benefits. The reason is straightforward: cost. GLP-1 agonists are expensive, and MCOs face strong financial incentives to restrict access to high-cost medications, particularly when those medications are being prescribed for obesity rather than diabetes — a distinction that matters enormously under Medicaid.

This also explains the plateau the researchers identified. MCO GLP-1 RA availability has hovered below 60% since 2022, showing essentially no meaningful improvement despite growing clinical evidence and advocacy. The FFS side of Medicaid showed more progress over the 2020 to 2024 period, but the majority of enrollees are in MCO plans, which means the aggregate access picture has stagnated.

Race, Insurance, and Who Gets the Prescription

Coverage on a formulary and actually receiving a prescription are two different things. Even when GLP-1 medications are technically available, the research shows that racial and ethnic disparities shape who gets them in clinical practice.

A 2026 retrospective study published in Obesity examined 2,060 patients at a large tertiary care center in Massachusetts, analyzing appointments before and after a significant MassHealth (Massachusetts Medicaid) policy change in early 2024 that expanded coverage for anti-obesity medications including semaglutide and tirzepatide. The findings before the policy change were stark. In January 2024, Black patients were 49% less likely to be prescribed semaglutide or tirzepatide compared to white patients, and Hispanic patients were 47% less likely, after adjusting for multiple variables. Patients with private insurance were nearly three times more likely to receive these medications than those without, and patients with established provider relationships had a significant advantage as well.

Then came April 2024, after MassHealth expanded coverage. The racial and ethnic disparities in prescription largely disappeared. The only group still significantly less likely to receive a prescription was those whose race was listed as “Not Disclosed” — a data artifact rather than a true demographic pattern. This is a powerful finding. It suggests that the racial disparities observed in GLP-1 prescribing are not primarily driven by physician bias or patient preference, but by insurance coverage. When Medicaid covers the drug, the playing field levels substantially.

A nationally representative study adds important context here. A 2024 analysis published in the Journal of General Internal Medicine used Medical Expenditure Panel Survey data from 2018 and 2019 to examine racial disparities in novel diabetes medication use — including GLP-1 receptor agonists and SGLT2 inhibitors — across different insurance types. Among privately insured patients, white individuals used these medications at a rate of 16.1% compared to 8.3% among non-white individuals, a substantial and statistically significant disparity. The gap was smaller but still present among Medicare beneficiaries. Among Medicaid enrollees, however, there was no statistically significant racial disparity in medication use — 10.0% for white patients versus 9.0% for non-white patients. The equalization under Medicaid held.

What the data suggest is a nuanced but important conclusion: Medicaid, when it covers these medications, functions as an equalizer. The private insurance market, with its variable formularies and significant cost-sharing, amplifies existing disparities. But Medicaid’s coverage restrictions mean that while the disparity may be smaller within the program, the overall prescription rate remains low — roughly 9 to 10% across racial groups. Everyone has similarly limited access, not equally good access. The equity is in shared scarcity rather than shared abundance.

For men on Medicaid with diabetes or obesity, this research underscores why advocacy — both individual and systemic — matters. If your state’s Medicaid plan restricts GLP-1 access, pushing back through your provider, requesting a prior authorization appeal, or understanding whether a different managed care plan in your state offers better formulary coverage can make a real difference. Policy changes, as the Massachusetts case demonstrates, can rapidly shift clinical outcomes for entire populations.

Medicare, the IRA, and the Complex Math of Drug Affordability

Medicaid is not the only public insurance program grappling with GLP-1 access. Medicare — which covers men 65 and older, as well as those with certain disabilities — has its own evolving landscape shaped by recent legislation.

The Inflation Reduction Act of 2022 introduced significant reforms to Medicare Part D that took effect in 2025, most notably a $2,000 annual out-of-pocket cap designed to eliminate the infamous coverage gap, or “donut hole,” that had plagued beneficiaries for years. The intent was clearly to make medications more affordable. But a 2026 retrospective analysis published in American Journal of Health-System Pharmacy found that insurers responded to these reforms in ways that may complicate GLP-1 access in practice.

The researchers compared Medicare Part D plans — both standalone prescription drug plans and Medicare Advantage prescription drug plans — between January 2024 and January 2025. Mean annual deductibles rose significantly in both plan types, with Medicare Advantage deductibles jumping from an average of $98.70 to $249.00. Co-insurance rather than fixed co-pay structures became dramatically more common for tier 3 medications in Medicare Advantage plans, rising from 6.3% to 38.1% in a single year. For GLP-1 agonists specifically, while overall formulary coverage declined slightly, coverage expanded for preferred drugs including subcutaneous semaglutide and tirzepatide. The catch is in the first-fill costs. The proportion of plans where a patient’s first fill of a GLP-1 medication would exceed $600 rose from the 40 to 45% range in 2024 to over 80% in standalone drug plans by 2025. Even if the annual out-of-pocket cap eventually benefits long-term adherent patients, the upfront cost burden may prevent men from filling their first prescription at all — a well-documented driver of non-adherence in pharmacoepidemiology research.

This matters practically because a man who picks up his first semaglutide prescription, sees a $700 bill at the pharmacy counter, and walks away without the medication never reaches the point where the annual cap protects him. The IRA reforms are a meaningful step forward in the aggregate, but the structural response from insurers has introduced new friction at the pharmacy counter that policymakers likely did not fully anticipate. If you are on Medicare and pursuing GLP-1 therapy, understanding your plan’s deductible structure and tier placement of specific agents before the plan year begins — during open enrollment — is not optional. It is essential financial planning.

The broader picture on GLP-1 use continues to expand rapidly despite these barriers. A 2024 JAMA data brief drawing on Medical Expenditure Panel Survey data documented a dramatic surge in GLP-1 medication use for type 2 diabetes across the United States, reflecting both the growth of the drug class and increasing clinical recognition of its cardiovascular benefits. But that surge has been unequally distributed, and the men most likely to be left behind are those on public insurance with the fewest resources to navigate a complex and often deliberately opaque coverage system.

What This Means For You

If you are on Medicaid and your physician recommends a GLP-1 medication for diabetes management, the first step is to understand whether your specific plan — not just your state’s program in the abstract — covers the medication without prior authorization. Medicaid managed care plans within the same state can have dramatically different formularies, and some plans offer better access than others. Asking your provider to submit a prior authorization request, even if it is likely to require documentation, keeps the process moving and creates a paper trail for appeals.

If you are on Medicare, do your homework during open enrollment. Formulary placement, deductible structure, and whether your specific GLP-1 medication is listed as a preferred agent can mean the difference between a manageable co-pay and a first-fill cost that derails treatment before it starts. Medicare’s plan finder tool exists for this reason, and your pharmacist is often a better resource than your insurance company’s customer service line when it comes to understanding real-world costs.

If you have private insurance, the research suggests your plan likely offers greater access, but racial and socioeconomic disparities in who actually receives prescriptions remain significant. Prior authorization requirements are common, and step therapy — requiring you to fail on a cheaper medication before the insurer approves the one your physician actually recommended — is widespread. Document everything, work with your physician’s office staff on appeals, and understand that persistence in this system is not optional but necessary.

And if GLP-1 medications are not accessible to you right now, that does not mean your metabolic health journey is on pause. These medications are powerful tools, but they function best as part of a broader lifestyle framework that includes resistance training to preserve lean mass, a protein-sufficient diet to support metabolic health, and the kinds of consistent behavioral habits that no drug can fully replicate. The science on GLP-1 access matters because equitable access to effective medicine is a legitimate health equity issue — but the foundation of metabolic health is built on fundamentals that remain accessible to every man regardless of what his insurance card says.

The data are clear: millions of men who could benefit from GLP-1 medications are not getting them, and the barriers are structural, not clinical. Understanding that system is the first step to navigating it — or to demanding something better.